title: Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity.
abstract: Angiogenesis is an important hallmark in multiple myeloma (MM) pathogenesis, with the participation of various versatile molecules. Interleukin-20 (IL-20) is a pro-inflammatory cytokine with diverse angiogenic properties. Our purpose was to estimate the possible impact of IL-20 on MM angiogenesis and disease activity. We measured serum levels of IL-20 along with levels of vascular endothelial growth factor (VEGF), basic-fibroblast growth factor and angiopoietin 2 in 58 active MM myeloma patients, in 32 of them who responded to bortezomib-based therapy and in 20 controls. We also measured bone marrow microvasclular density (MVD) by immunohistochemical method. Serum levels of all cytokines and bone marrow MVD were higher in active MM patients compared to controls and responders to bortezomib-based therapy (p < 0.001 in all cases). They were also in parallel with International Staging System stages (p < 0.001 for all cases). Serum levels of IL-20 correlated positively with levels of angiogenic cytokines and bone marrow MVD (p < 0.01 for MVD, p < 0.002 for VEGF and p < 0.001 for the other cases). Our results strongly suggest that serum IL-20 concentrations participate actively in the pathophysiology of MM progression. Therefore, it could be used as an indicator of the disease progression and angiogenesis processes.
authors: Dept of Heamatology, University Hospital of Heraklion, PO Box 1352, 71110, Heraklion, Greece, alexandm@med.uoc.gr.
authors: M G
authors: MG
authors: Alexandrakis
authors: C A
authors: CA
authors: Pappa
authors: M
authors: M
authors: Kokonozaki
authors: A
authors: A
authors: Boula
authors: R
authors: R
authors: Vyzoukaki
authors: D
authors: D
authors: Staphylaki
authors: A
authors: A
authors: Papadopoulou
authors: N
authors: N
authors: Androulakis
authors: G
authors: G
authors: Tsirakis
authors: A
authors: A
authors: Sfiridaki
mesh_terms: D000368:Aged; D042702:Angiopoietin-2 / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001853:Bone Marrow / Q000098:blood supply / Q000473:pathology; D000069286:Bortezomib / Q000627:therapeutic use*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood; D006801:Humans; D007378:Interleukins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000097:blood* / Q000473:pathology; D012016:Reference Values; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: C586513:ANGPT2 protein, human; D042702:Angiopoietin-2; D000970:Antineoplastic Agents; D007378:Interleukins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D000069286:Bortezomib; C422042:interleukin 20
references: Cell. 2001 Jan 12;104(1):9-19
references: 11163236
references: J Cell Sci. 2005 Feb 15;118(Pt 4):771-80
references: 15687104
references: Blood. 2000 Apr 15;95(8):2630-6
references: 10753844
references: Haematologica. 2003 Feb;88(2):176-85
references: 12604407
references: Biochem Biophys Res Commun. 2005 Jul 29;333(2):470-5
references: 15950941
references: Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15364-9
references: 17878297
references: J Biomed Sci. 2006 Sep;13(5):601-12
references: 16703417
references: Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2090-5
references: 16778121
references: Genes Immun. 2006 Apr;7(3):234-42
references: 16511554
references: Eur J Cancer. 2011 Aug;47(12):1908-18
references: 21565488
references: Ann Hematol. 2000 Oct;79(10):574-7
references: 11100749
references: Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):327-34
references: 17537668
references: Cell Transplant. 2014;23(4-5):631-9
references: 24816455
references: J Immunol. 2009 Apr 15;182(8):5003-12
references: 19342680
references: Microcirculation. 2003 Jun;10(3-4):371-9
references: 12851653
references: Eur J Intern Med. 2012 Jun;23 (4):368-73
references: 22560388
references: Eur J Cancer. 2006 Jul;42(11):1564-73
references: 16765041